The current findings in the mouse appear relevant for human T-ALL. The (partial) loss of Tcf1 is now also reported in a subset of pediatric T-ALL, the ETP group, in which deletions of TCF7 were found in two patients (Yu et al., 2012) . MEF2C has recently been shown to act as the master transcriptional regulator of genes that constitute the signature of ETP-ALL (Homminga et al., 2011) . Interestingly, gene expression profiling of Tcf7 À/À lymphomas shows upregulated expression of Mef2c (Tiemessen et al., 2012) , further supporting the possibility that lack of Tcf1 may be involved in development of certain ETP-ALL cases.
The unexpected finding that Tcf1 is a tumor suppressor gene also indicates that Tcf1 and Lef1 are not merely redundant in the thymus. For normal T cell development, a deficiency in both Lef1 and Tcf1 results in a more profound arrest in thymocyte differentiation than seen with Tcf1 alone (Yu et al., 2012) , indicating a redundant role of these two factors. However, for the development of T cell lymphomas, Lef1 is the culprit leading to cellular transformation, whereas Tcf1 can function as transcriptional repressor of Lef1, in the role of a classical tumor suppressor gene. How this dichotomous cooperative although antagonistic relationship between these two DNA-binding factors is regulated and if Wnt signaling plays a role in this regulation is currently not understood (Figure 1, bottom) .
Tcf1 has been shown to act as commitment factor for the T cell lineage in hematopoietic stem cells in gain-offunction experiments (Weber et al., 2011) , a finding that was not corroborated by the loss-of-function experiments reported by Yu et al. (2012) . This may indicate that yet another Tcf related factor, for instance Tcf4, can partially compensate for loss of both Tcf1 and Lef1, because inhibition of canonical Wnt signaling blocks thymopoiesis at DN1. Whether the dual roles that Tcf1 plays in T cell development are intrinsically different from the roles of Lef1 or merely determined by stoichiometry and abundance of various splice variants (in different lineages or developmental stages) remains to be determined. Nevertheless, the T cell-specific tumor suppressor function of Tcf1 that is best known as an activator of the Wnt pathway is an unexpected twist. Guo, Z., Dose, M., Kovalovsky, D., Chang, R., O'Neil, J., Look, A.T., von Boehmer, H., Khazaie, K., and Gounari, F. (2007) . Blood 109, 5463-5472.
Homminga, I., Pieters, R., Langerak, A.W., de Rooi, J.J., Stubbs, A., Verstegen, M., Vuerhard, M., Buijs-Gladdines, J., Kooi, C., Klous, P., et al. (2011) In this issue of Immunity, Yu et al. (2012) outline a fascinating model in which TLR7-mediated antibody production acts as a dominant immunosurveillance mechanism against endogenous retroviruses (ERVs), with additional support of TLR3 and TLR9 that function to prevent ERV-mediated malignancy.
Our innate immune system has evolved several pattern recognition receptors (PRRs) to sense microbial nucleic acids. A prominent group of these PRRs constitutes the subfamily of Toll-like receptors (TLRs) that has evolved to sense ssRNA and short dsRNA (TLR7, TLR8), DNA (TLR9), or long dsRNA (TLR3). Upon ligand recognition, TLR activation sets off signaling cascades that are geared toward the eradication of the microbial pathogen, ranging from the activation of immediate effector functions to the initiation of adaptive immune responses (Kawai and Akira, 2011) .
A large proportion of the mammalian genome is made up of fossils of Immunity transposable elements and a major part of these remnants are derived from endogenous retroviruses (ERVs) (Stocking and Kozak, 2008; Stoye, 2012) . ERVs are the result of exogenous retroviruses (XRVs) that have integrated within the germline of the host, thereby subjecting the provirus to mendelian inheritance. Most ERVs have lost their capability to propagate because of numerous inactivating mutations, yet a considerable number of active ERVs has been documented in the murine system (Stoye, 2012) . Among these, the best-studied ERVs can be found within the class I ERVs that are closely related to the gamma retrovirus genus of XRVs, typified by murine leukemia viruses (MuLVs). MuLVs are well known for their ability to induce oncogenic transformation leading to leukemia in mice and as such they have been studied extensively. Germline-encoded provirus, with the potential of giving rise to infectious MuLVs with ecotropic host range, are found in low copy number in various inbred mouse strains, and the commonly used laboratory strain C57BL/ 6 harbors the provirus of a defective endogenous ecotropic MuLV (E-MuLV) on chromosome 8 (Emv2). Emv2 harbors a point mutation in its pol region that prevents its propagation a priori. In addition, its so-called N-tropism encoded in its gag region would restrict its growth in C57BL/6 mice that express the allele combination Fv-1 b/b , which encodes for a restriction factor for N-tropic viruses (Stocking and Kozak, 2008) . Mechanistically, Emv2 reactivation is most probably due to in trans complementation of its defects by nonecotropic ERVs, an event that can be triggered by genetic (crossbreeding) or environmental (e.g., inflammation) factors (Greenberger et al., 1975; McCubrey and Risser, 1982) . Nonetheless, under normal conditions inbred C57BL/6 mice do not display E-MuLV viremia that would lead to disease pathology. Next to dedicated restriction factors that prevent propagation of endogenous and exogenous MuLVs in a cell-intrinsic fashion (Stoye, 2012) , it has been shown that exogenous MuLV infection in ERV-negative inbred mouse strains is effectively controlled by a TLR7-dependent antibody response (Browne, 2011; Kane et al., 2011 
indicating that absence of TLR7 alone was sufficient and necessary for the virus to propagate. In line with this notion, mice deficient in upstream or downstream components of the TLR7 signaling cascade also displayed increased retroviral gene expression. However, whereas TLR7 deficiency led to retroviremia in these mice, only Tlr3
animals displayed T-ALLs. Subsequent studies indicated that none of the T cell populations within the thymus showed significant endosomal TLR expression, yet the cortical thymic epithelial cells and plasmacytoid dendritic cells expressed them, suggesting that TLRmediated protection against ERV propagation operates in a cell-extrinsic manner. The pol region within retroviral RNAs from T-ALL lines revealed strong homology to the endogenous Emv2 provirus, with a correction of its mutation. This is highly indicative of recombination events between Emv2 and one or more nonecotropic viruses subsequently giving rise to a replication competent retrovirus. Studying ERV integration at the genomic level, the authors observed that Tlr3
Tlr7
À/À Tlr9 À/À mice displayed multiple integrations events in lymphoid tissue and most prominently in tumor cell clones. Surprisingly, yet in line with the tumor data, only Tlr3
mice, but no other ERV viremic mice (e.g., Tlr7 À/À ), showed additional proviral integrations at the genomic level, at least when using Southern blot to probe for such events. A common driver in retrovirus-mediated oncogenesis is the activation of proto-oncogenes by the integration of proviral DNA in vicinity to these genes. In line with this, the authors observed frequent genomic ERV reintegration events within proximity to coding sequences of proto-oncogenes in T-ALL cell lines of Tlr3
Analyzing the serum from different genotypes for the presence of anti-ERVspecific IgG antibodies revealed an inverse picture as compared to the ERV expression data. Mice devoid of active ERVs displayed high amounts of anti-ERV-specific IgG antibodies, and these antibodies were also able to inhibit the replication of an exogenous MuLV in vitro. Interestingly, despite comparable titers, anti-ERV serum from wild-type mice showed the highest inhibitory activity, whereas serum from Tlr3
was less effective. Yu et al. (2012) suggest that de novo ERV reactivation occurs spontaneously in wild-type C57BL/6 mice ( Figure 1) . The exact location, timing, and mechanism of this reactivation is unclear, yet its occurrence is unequivocally documented by the high and specific class-switched ERV antibody titers. This is in line with early studies that have reported the phenomenon of ''autogenous'' anti-ERV immunity in inbred mouse strains in the absence of retroviremia (Hanna et al., 1972) . The fact that TLR7 plays a nonredundant role in the induction of protective antibody titers in response to ERV reactivation is intriguing, yet not unexpected given previous studies exploring the role of TLR7 in adaptive immune responses toward XRVs (Browne, 2011; Kane et al., 2011) . However, Yu et al. (2012) refine and extend this concept by demonstrating a nonredundant role for TLR7 in the immunosurveillance of endogenous retroviruses. Extrapolating results from studies with exogenous MuLVs predicts that B cell-intrinsic TLR7 activation is instrumental for this protection (Browne, 2011) .
Theoretically, loss of TLR7 signaling could also be positioned upstream of the observed ERV reactivation event through an indirect mechanism that is unrelated to the role of TLR7 in orchestrating the antiretroviral antibody response. However, this scenario appears less likely given the well-documented role of TLR7 in directing antiretroviral immunity and the strict inverse correlation of ERVspecific antibody titers and viremia as a function of TLR7 expression. Nevertheless, it has to be considered that a dysfunctional TLR7 axis and more so a complete lack in nucleic acid-sensing TLRs could also have an impact on the reactivation and propagation of the ERVs themselves, independently of the specific anti-ERV response. Indeed, it is conceivable that Tlr3
animals display a dysfunctional immune system that could lead to secondary events facilitating the reactivation of ERVs. Indeed, in a recent study by Young et al. (2012) , the lack of functional B cell immunity was also identified as a critical component for ERV reactivation. However, Young et al. (2012) positioned lack of antibody production upstream of ERV reactivation rather than functioning as an endogenous ERV surveillance mechanism. More specifically, a dysregulation of the intestinal microbiome in the absence of B cell immunity was suggested to trigger inflammation leading to ERV reactivation. Further studies will be required to reconcile these two models.
Another intriguing finding is that only the additional absence of TLR3 and TLR9 results in tumorigenesis in ERV-viremic, TLR7-deficient animals.
The authors suggest that this could be due to a qualitative difference in the adaptive immune response of the host. Indeed, neutralization experiments with sera from wild-type versus Tlr3 À/À , Tlr9 À/À , or Tlr3 À/À Tlr9 À/À mice alludes to a qualitative difference of the anti-ERV sera. Moreover, the different repertoire of antigens being recognized by these sera points into the same direction. As such, it is possible that T cell help provided indirectly by TLR3 and TLR9 activation drives the formation of a more effective antibody repertoire. Another likely scenario is that TLR3 and TLR9 could be instrumental for the initiation of cytotoxic CD8 + T cell responses, a phenomenon that is known to be independent of TLR7 in the context of exogenous MuLV infection (Browne, 2011). TLR3, for example, plays an important role in cross priming antigen-specific CD8 + T cells and it is possible that this mechanism accounts for the induction of cytotoxic T cell responses eliminating transformed T cells. At the same time, it should also be considered that the additional absence of TLR3 and/or TLR9 could indirectly shape a different MuLV ''repertoire,'' which could lead to the observed malignant transformation. In this respect, it would be very informative to obtain full sequences of the ERV repertoire arising in the different genedeleted mouse strains. In summary, Yu et al. (2012) unravel a pivotal role for nucleic acid-sensing TLRs in the immunosurveillance of endogenous retroviruses, with TLR7 playing a dominant role in inhibiting ERV viremia in the first place and TLR3 and TLR9 playing a secondary but significant role in preventing retroviral-induced malignancy. In the absence of clear evidence showing a role for ERVs in human diseases, it remains speculative whether similar protective mechanisms are at play in the human system and how they impact disease. Nevertheless, primed by this study we may now be looking for a possible protective role for ERV immunosurveillance in humans. 
